Navigation Links
PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Date:11/20/2007

BOSTON, Nov. 20 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global bio/pharmaceutical services organization, has appointed Dr. Victor Kiri, formerly with GlaxoSmithKline, as Director of Pharmacoepidemiology within the Company's Clinical Research Services business. Dr. Kiri's responsibilities include advising clients in the design and conduct of comparative observational studies, offering epidemiological analysis for compounds in development, and guiding strategic decisions regarding future areas of research and product development.

"Regulatory pressures are increasing client demand for pharmacoepidemiological assessments and related studies as part of late phase clinical development," said Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics at PAREXEL International. "One of PAREXEL's strengths is our late phase development service offering that we call Peri-Approval Clinical Excellence or PACE. Dr. Kiri's in-depth experience in late phase study design and safety-related issues further expands our capabilities to provide clients with integrated pharmacoepidemiology and pharmacovigilance solutions."

"PAREXEL's PACE group has successfully implemented some of the largest and most complex trials of marketed products ever conducted, and I am pleased to be joining such a premier team of global experts," said Dr. Victor Kiri. "I look forward to contributing to PAREXEL's focused expertise in the area of pharmacoepidemiology, and working with clients to determine the right methods and approaches for their late phase studies."

Prior to joining PAREXEL, Dr. Kiri managed epidemiology research at GlaxoSmithKline. He previously served
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., the ... the proprietary Natural Killer (NK) cell-line platform, Neukoplast® ... Patrick Soon-Shiong , NantWorks founder, physician scientist ... agreement to purchase approximately $48 million of the ... the investment, he will be named Co-Chairman of ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... Subjects with ALS, RICHMOND, Calif., Sept. 3 ... it has opened a Phase,2 clinical trial (SB-509-801) to ... degenerative motor-neuron disease for which there,are limited treatment options ... injectable formulation of a plasmid,encoding a zinc finger DNA-binding ...
... , - This Analysis Showed That Multaq(R) (Dronedarone) ... Atrial Fibrillation or Atrial Flutter,Already Adequately Treated by Antithrombotic ... the data from the ATHENA study,were presented today at ... Cardiology congress 2008, in Munich, Germany. Previous results,from the ...
Cached Medicine Technology:Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5
(Date:12/25/2014)... 2014 The microscopy market is ... to reach $5,756.0 million by 2019. Optical microscopy ... The electron microscopes product segment is expected to ... , Rising focus on nanotechnology, technological advancements, and ... microscopy market. , Get Full Copy of Report ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... The short film “Color of Honor” by young ... a true 9/11 hero, Welles Remy Crowther. It has been ... hours of Nuremberg International Short Film Festival and the 8th ... screenwriter and director Luciana Lagana plays the mother of ... husband, Gregory Graham - Graham plays a heroic ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... WASHINGTON, Jan. 11 The Executive Council of the International ... to oppose any health care reform legislation that is funded ... , "For decades, IAM members exchanged substantial wage increases for ... "Now, in a bizarre turn of events, their insurance premiums ...
... , DUBLIN, Calif., Jan. 11 ... today announced it received an additional over-the-counter (OTC) clearance ... for its flagship product, TRIA Laser Hair Removal System ... hair reduction, making it the first and only at-home ...
... 2010 - A new study by a researcher at ... moods impact the number of prescriptions, referrals and lab ... they spend talking with their patients. The findings of ... to Tests and Specialists: Associations with Physician Burnout and ...
... a more strongly evidence-based approach to medicine would help ... nations and improve quality, access, efficiency, equity and healthy ... International Journal of Public Policy this month. ... Public Health, at the University of North Florida, in ...
... safe practices only about half the time, study finds, ... made for kids are getting better at portraying safety ... they,re still missing the mark about half the time. ... been tracking injury-prevention practices in movies since 1995. The ...
... , CHICAGO, Jan. 11 ... Stimulus Program , making it safe and easy for physicians ... qualify for significant federal incentives. , (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ... a guarantee that the Allscripts EHR they select will meet ...
Cached Medicine News:Health News:Machinists Union Leaders Vote to Oppose Health Benefits Tax 2Health News:FDA Grants Permanent Hair Reduction Labeling for TRIA Laser Hair Removal System 2Health News:Considering the evidence in health care 2Health News:Seat Belts, Bike Helmets Go Unused in Movies Aimed at Kids 2Health News:Seat Belts, Bike Helmets Go Unused in Movies Aimed at Kids 3Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 2Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 3Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 4Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 5Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 6
Tilt Adapter for the 8000 Sliding Microtome to allow for orientation of the specimen....
... Microtome has a look that is revolutionary, a ... functions and capabilities that will please the most ... experience and knowledge but still breaking new ground ... will be the answer to many of your ...
Clock oil, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Medicine Products: